Called Phesgo, the new product contains the active substances in Herceptin (trastuzumab) – already facing lower-cost competition in the US and Europe – and Perjeta (pertuzumab), which are both ...

Phesgo has been approved by the EU for same indications as Herceptin/Perjeta – in combination with chemotherapy in early HER2-positive breast cancer (pre- and post-surgery) as well as for front ...

Halozyme now has several marketed partnered drugs based on this technology, including the subcutaneous formulation of J&J’s JNJ Darzalex and Roche’s Phesgo. The company’s top line comprises ...

The top-line growth was primarily driven by higher royalty payments from Roche RHHBY for Phesgo and J&J JNJ for subcutaneous Darzalex (daratumumab) as well as an increase in milestone revenues ...

Sales in the Pharmaceuticals Division grew 8% in 2024 to CHF 46.2 billion, driven by strong growth in demand for its key drugs, namely Vabysmo (severe eye diseases), Phesgo (breast cancer ...

Our 2024 royalty revenue exceeded guidance driven by continued strong growth of DARZALEX SC and Phesgo, with modest initial contribution from VYVGART Hytrulo resulting from growing adoption and ...

Key drivers are DARZALEX subcutaneous, Phesgo, and VYVGART Hytrulo. CFO Nicole LaBrosse emphasized strong Q4 financial results, including a 30% increase in revenue to $298 million and a 61% rise ...